BlackRock Group’s Kite Pharma, Inc. KITE Stock Holding History

BlackRock Group’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.31M	Buy	29,186 +2,423	+9%	+$119K	﹤0.01%	2004
2016 Q3	$1.49M	Sell	26,763 -2,824	-10%	-$157K	﹤0.01%	1820
2016 Q2	$1.48M	Sell	29,587 -229	-0.8%	-$11.3K	﹤0.01%	1742
2016 Q1	$1.37M	Buy	29,816 +10,303	+53%	+$499K	﹤0.01%	1756
2015 Q4	$1.2M	Buy	19,513 +5,943	+44%	+$418K	﹤0.01%	1778
2015 Q3	$755K	Buy	13,570 +6,206	+84%	+$390K	﹤0.01%	2038
2015 Q2	$449K	Sell	7,364 -17	-0.2%	-$970	﹤0.01%	2306
2015 Q1	$426K	Sell	7,381 -18,582	-72%	-$1.25M	﹤0.01%	2258
2014 Q4	$1.5M	Buy	25,963 +24,521	+1,700%	+$1.03M	﹤0.01%	1637
2014 Q3	$41K	Buy	+1,442	New	+$35.7K	﹤0.01%	2708

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

BlackRock Group's KITE Position: Q4 2016 in Review

BlackRock Group increased its Kite Pharma, Inc. (KITE) stake by 9.1% in Q4 2016, buying an estimated $119K and bringing the position to 29,186 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

BlackRock Group first reported a position in KITE in Q3 2014 and has held it in 10 quarters since. The position peaked at $1.5M in Q4 2014. 184 funds tracked by Wall St. Rank hold KITE as of Q4 2016.

BlackRock Group held 29,186 shares of Kite Pharma, Inc. worth $1.31M as of Q4 2016.
BlackRock Group bought 2,423 Kite Pharma, Inc. shares in Q4 2016, an estimated $119K.
Kite Pharma, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2004 holding.
BlackRock Group first reported a position in Kite Pharma, Inc. in Q3 2014 and has held it in 10 quarters since.
BlackRock Group's Kite Pharma, Inc. position peaked at $1.5M in Q4 2014.
184 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.